A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2018
At a glance
- Drugs RGX 314 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors REGENXBIO
- 08 Feb 2018 According to a REGENXBIO media release, dosing of the third cohort of six patients in this study has been completed.
- 04 Jan 2018 According to a REGENXBIO media release, company expects to complete enrollment in this trial in first half of 2018 and top-line data is expected in late 2018.
- 08 Nov 2017 According to a REGENXBIO media release, following a scheduled review by an independent Data Safety and Monitoring Board (DSMB), the Company expects to initiate dosing of the third cohort in the Phase I clinical trial by the first quarter of 2018.